The role of health technology assessment bodies in shaping drug development. - Wikidata - wikimedia - TriplyDB

The role of health technology assessment bodies in shaping drug development.

The role of health technology assessment bodies in shaping drug development.

http://www.wikidata.org/entity/Q34524056

about

Comparative effectiveness research and its utility in In-clinic practice Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.Adoption of trastuzumab for breast cancer in four emerging countries in the use of health technology assessment: a case study.Benefit-Risk Analysis for Decision-Making: An Approach.A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.Evolving role of pharmaceutical physicians in medical evidence and education

P2860

Q26767184-AE3673E7-825A-4D7B-8A79-FAE97A0A68DB Q33845622-09FD0CB1-0CBE-42BA-8614-5C2FA334E025 Q37474165-413C5C2D-19EC-4F2E-91D8-5661C9BB8413 Q38784158-4869F6CE-B1E2-412A-A750-8E7A15DE7757 Q39664372-4A734FB3-E1F2-4601-846F-6D7922B3DB15 Q48770147-9BB9689D-B3B4-4B4B-A066-34FAF7759EA8 Q53001245-C4A623AF-3D24-40A4-A3A4-6F37ECB21FFB Q59125752-93B2C9A5-01A8-4F3F-96E9-CFE6F7B923E9

P2860

The role of health technology assessment bodies in shaping drug development.

http://www.wikidata.org/entity/Q34524056

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The role of health technology assessment bodies in shaping drug development.

@ast

The role of health technology assessment bodies in shaping drug development.

@en

The role of health technology assessment bodies in shaping drug development.

@nl

type

label

The role of health technology assessment bodies in shaping drug development.

@ast

The role of health technology assessment bodies in shaping drug development.

@en

The role of health technology assessment bodies in shaping drug development.

@nl

prefLabel

The role of health technology assessment bodies in shaping drug development.

@ast

The role of health technology assessment bodies in shaping drug development.

@en

The role of health technology assessment bodies in shaping drug development.

@nl

P1433

Q34524056-CBC693F3-028F-40D3-A974-2CF58198CEE7

P1476

Q34524056-32CC7B76-2A2D-45F1-82BB-2AE405C69F77

P2093

Q34524056-54CDD8D1-A0AB-4967-B492-6A24972FF28D

Q34524056-D53FC77C-159E-49F9-938D-C6D81C6CF806

P2860

Q34524056-0A655F52-C77F-4B08-9A62-09527971511C

Q34524056-1989A6AC-F3F9-4F08-87FA-DDD89040D0F7

Q34524056-1A55F6FB-C50D-40E5-9504-A05F98C13C67

Q34524056-1F93F03C-FFF1-4018-9D75-281C803B4CE1

Q34524056-27B3F347-7162-4083-B08A-961164B666BE

Q34524056-293159CB-B159-4F00-AC09-D08F7DFCFB42

Q34524056-2FC191C7-F74C-4CB5-AE6E-A4F44E2EC622

Q34524056-3DFAD970-0EC7-4BA5-A553-E0777BF77DE1

Q34524056-4428CD7F-297B-4CAC-AE45-8AC13F4068AE

Q34524056-464BB2D7-6347-4AED-8377-46C286334489

P304

Q34524056-CDC52576-271A-4F94-94C3-C88CFBE606D5

P31

Q34524056-1D7C2449-40FB-48F1-B47B-55CE1025EB96

P356

Q34524056-03C0A7B1-CB15-4410-AA18-CE470F3387E8

P407

Q34524056-51E2BADE-D0B0-488D-B60B-196A70AD7941

P478

Q34524056-B171DCAA-1737-4661-9B63-AE635E510096

P577

Q34524056-9362A376-62A1-42B2-8DDD-BB8BBBCA859B

P5875

Q34524056-96BF79EB-124E-46BA-9F28-CF2DAB75C553

P698

Q34524056-A7386F1C-BF78-4D02-AC82-74ECAFEB3227

P932

Q34524056-E04330AD-681B-4854-9A7E-9CE4FC35C794

P356

P1433

Drug Design, Development and Therapy

P1476

The role of health technology assessment bodies in shaping drug development.

@en

P2093

Claudio Jommi

http://www.w3.org/2001/XMLSchema#string

Oriana Ciani

http://www.w3.org/2001/XMLSchema#string

P2860

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

EBM, HTA, and CER: clearing the confusion

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Mapping of health technology assessment in selected countries.

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

Future relevance of genetic testing: a systematic horizon scanning analysis.

The last decade of Italian pharmaceutical policy: instability or consolidation?

Introduction of new technologies and decision making processes: a framework to adapt a Local Health Technology Decision Support Program for other local settings.

P304

2273-2281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S49935

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268787481

http://www.w3.org/2001/XMLSchema#string

P698

25419117

http://www.w3.org/2001/XMLSchema#string

P932

4234281

http://www.w3.org/2001/XMLSchema#string